Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Parkinson Disease (drug therapy) And NotChristopher G. Goetz

List of bibliographic references

Number of relevant bibliographic references: 83.
Ident.Authors (with country if any)Title
000034 Mathieu Favier [France] ; Theo Duran ; Carole Carcenac ; Guillaume Drui ; Marc Savasta ; Sebastien CarnicellaPramipexole reverses Parkinson's disease-related motivational deficits in rats.
000060 Erwan Bezard [France] ; Elisabetta Tronci ; Elsa Y. Pioli ; Qin Li ; Gregory Porras ; Anders Björklund ; Manolo CartaStudy of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
000071 Alexandre Krainik [France] ; Audrey Maillet ; Vanessa Fleury ; Mehmet Sahin ; Irène Troprès ; Laurent Lamalle ; Stephane Thobois ; Valerie Fraix ; Marjorie Villien ; Jan Warnking ; Pierre Pollak ; Serge Pinto ; Paul KrackLevodopa does not change cerebral vasoreactivity in Parkinson's disease.
000075 Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François TisonEncephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
000087 Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000098 Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. MolineDonepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
000105 Erwan Bezard [France] ; Zhenyu Yue [États-Unis] ; Deniz Kirik [Suède] ; Maria Grazia Spillantini [Royaume-Uni]Animal Models of Parkinson’s Disease: limits and relevance to neuroprotection studies
000151 Julia Grossac [France] ; Stéphanie Ruiz [France] ; Emmanuelle Bondon-Guitton [France] ; Franck-Emmanuel Roux [France] ; Olivier Fourcade [France] ; Jean-Louis Montastruc [France] ; Thomas Geeraerts [France]Severe intracranial bleeding related to vitamin K Antagonist‐Ropinirole interaction
000157 Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
000179 Estelle Dellapina [France] ; Angélique Gerdelat-Mas [France] ; Fabienne Ory-Magne [France] ; Laure Pourcel [France] ; Monique Galitzky [France] ; Fabienne Calvas [France] ; Marion Simonetta-Moreau [France] ; Claire Thalamas [France] ; Pierre Payoux [France] ; Christine Brefel-Courbon [France]Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
000194 Joaquim J. Ferreira [Portugal] ; Dulce Neutel [Portugal] ; Tiago Mestre [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Skin cancer and Parkinson's disease
000198 Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study
000199 Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
000200 Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
000206 Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
000208 Jean-Louis Montastruc [France] ; Anne Charlotte Danton [France] ; Genevieve Durrieu [France] ; Isabelle Lacroix [France] ; Pascale Olivier [France] ; Agnés Sommet [France] ; Jean-Michel Senard [France]Neuropathy as a potential complication of levodopa use in Parkinson's disease: A Pharmacological and Pharmacovigilance point of view
000211 Fanny Pineau [France] ; Michael Schüpbach [France] ; Jean-Christophe Corvol [France] ; Constance Flamand-Rouvière [France] ; Marie Vidailhet [France] ; Emmanuel Roze [France]Long‐standing paraphilia induced by dopamine agonists in Parkinson's disease
000217 Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
000222 Laurence Nègre-Pagès [France] ; Hélène Grandjean [France] ; Maryse Lapeyre-Mestre [France] ; Jean Louis Montastruc [France] ; Annie Fourrier [France] ; Jean Pierre Lépine [France] ; Olivier Rascol [France]Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study
000231 Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]Validation of the freezing of gait questionnaire in patients with Parkinson's disease
000234 Kiyoka Kinugawa [France] ; Emmanuel Itti [France] ; Jean-Francois Lepeintre [France] ; Ivan Mari [France] ; Virginie Czernecki [France] ; Francoise Heran [France] ; Stephane Clemenceau [France] ; Marie Vidailhet [France] ; Emmanuel Roze [France]Subacute dopa‐responsive parkinsonism after successful surgical treatment of aqueductal stenosis
000235 Caroline Moreau [France] ; Luc Defebvre [France] ; David Devos [France] ; Fabio Marchetti [Italie] ; Alain Destée [France] ; Alessandro Stefani [Italie] ; Antonella Peppe [Italie]STN versus PPN‐DBS for alleviating freezing of gait: Toward a frequency modulation approach?
000240 David Devos [France]Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
000247 David Maltête [France] ; Nathalie Chastan [France] ; Stéphane Derrey [France] ; Bertrand Debono [France] ; Emmanuel Gérardin [France] ; Romain Lefaucheur [France] ; Bruno Mihout [France] ; Didier Hannequin [France]Microsubthalamotomy effect at day 3: Screening for determinants
000252 Nathalie Chastan [France] ; Manh Cuong Do [France] ; Fabrice Bonneville [France] ; Frédéric Torny [France] ; Frédéric Bloch [France] ; G. W. Max Westby [France] ; Didier Dormont [France] ; Yves Agid [France] ; Marie-Laure Welter [France]Gait and balance disorders in Parkinson's disease: Impaired active braking of the fall of centre of gravity
000260 Paul Sauleau [France] ; Emmanuelle Leray [France] ; Tiphaine Rouaud [France] ; Sophie Drapier [France] ; Dominique Drapier [France] ; Sophie Blanchard [France] ; Gwenolla Drillet [France] ; Julie Péron [France] ; Marc Vérin [France]Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson's disease
000263 Karim Farid [France] ; Igor Sibon [France] ; Dominique Guehl [France] ; Emmanuel Cuny [France] ; Pierre Burbaud [France] ; Michèle Allard [France]Brain dopaminergic modulation associated with executive function in Parkinson's disease
000267 Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni]Adherence to antiparkinson medication in a multicenter European study
000304 Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Lévy [France] ; Eric Bardinet [France] ; Jérôme Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France]Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom
000308 C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000312 Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France]Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease
000314 Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
000321 Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France]Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
000322 Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
000353 Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
000357 Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne]Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
000369 Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni]Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
000371 Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
000377 Andre Machado [États-Unis] ; Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Alim-Louis Benabid [France]Deep brain stimulation for Parkinson's disease: Surgical technique and perioperative management
000395 Alexis Elbaz [États-Unis, France] ; Brett J. Peterson [États-Unis] ; James H. Bower [États-Unis] ; Ping Yang [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Shannon K. Mcdonnell [États-Unis] ; J. Eric Ahlskog [États-Unis] ; Walter A. Rocca [États-Unis]Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study
000406 Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
000407 Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; François Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France]Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
000424 Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France]Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
000432 C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies
000435 Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]Dopaminagonists and fibrotic valvular heart disease: Further considerations
000447 Sylvie Raoul [France] ; Mirella Faighel [France] ; Isabelle Rivier [France] ; Marc Vérin [France] ; Youenn Lajat [France] ; Philippe Damier [France]Staged lesions through implanted deep brain stimulating electrodes: A new surgical procedure for treating tremor or dyskinesias
000449 Bechir Jarraya [France] ; Anne-Marie Bonnet [France] ; Charles Duyckaerts [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Jean-Jacques Hauw [France] ; Yves Agid [France]Parkinson's disease, subthalamic stimulation, and selection of candidates: A pathological study
000455 Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
000456 Patrice Péran [France] ; Olivier Rascol [France] ; Jean-François Démonet [France] ; Pierre Celsis [France] ; Jean-Luc Nespoulous [France] ; Bruno Dubois [France] ; Dominique Cardebat [France]Deficit of verb generation in nondemented patients with Parkinson's disease
000460 Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; Jing Xie [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease
000470 Paul Krack [France] ; Valérie Fraix [France] ; Alexandre Mendes [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Postoperative management of subthalamic nucleus stimulation for Parkinson's disease
000475 Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France]Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
000482 Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Périna [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France]Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease
000508 Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
000510 Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
000518 Jean-Louis Montastruc [France]Treatment of Parkinson's disease should begin with a dopamine agonist
000534 Franck Durif [France] ; Marie Vidailhet [France] ; Bérangère Debilly [France] ; Yves Agid [France]Worsening of levodopa‐induced dyskinesias by motor and mental tasks
000535 Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Treatment of Parkinson's disease should begin with a dopamine agonist
000536 Christine Dentresangle [France] ; Laurent Veyre [France] ; Didier Le Bars [France] ; Christian Pierre [France] ; Frank Lavenne [France] ; Pierre Pollak [France] ; Jeanine Guerin [France] ; Jean-Claude Froment [France] ; Emmanuel Brousolle [France]Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study
000545 Yves Agid [France] ; E. Ahlskog [France] ; A. Albanese [France] ; D. Calne [France] ; T. Chase [France] ; J. De Yebenes [France] ; S. Factor [France] ; S. Fahn [France] ; O. Gershanik [France] ; C. Goetz [France] ; W. Koller [France] ; M. Kurth [France] ; A. Lang [France] ; A. Lees [France] ; P. Lewitt [France] ; D. Marsden [France] ; E. Melamed [France] ; P. P. Michel [France] ; Y. Mizuno [France] ; J. Obeso [France] ; W. Oertel [France] ; W. Olanow [France] ; Werner Poewe [France] ; Pierre Pollak [France] ; S. Przedzorski [France] ; N. Quinn [France] ; R. Raisman-Vozari [France] ; A. Rajput [France] ; F. Stocchi [France] ; E. Tolosa [France]Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint
000552 Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France]A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
000553 M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France]The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease
000556 Olivier Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
000558 H. Widner [Suède] ; G.-L. Defer [France]Dyskinesias assessment : From CAPIT to CAPSIT
000560 Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
000561 Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
000571 Bejjani [France] ; Philippe Damier [France] ; Isabelle Arnulf [France] ; Sawas Papadopoulos [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Yves Agid [France] ; Bernard Pidoux [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Claude Marsault [France]Deep brain stimulation in Parkinson's disease: Opposite effects of stimulation in the pallidum
000584 Derex [France] ; P. Trouillas [France]Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy
000591 Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
000601 Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France]Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease
000616 Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
000617 Limousin [France] ; Pierre Pollak [France] ; Abdelhamid Benazzouz [France] ; Dominique Hoffmann [France] ; Emmanuel Broussolle [France] ; Jean Edmond Perret [France] ; Alim-Louis Benabid [France]Bilateral subthalamic nucleus stimulation for severe Parkinson's disease
000619 Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France]A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine
000627 P. Krack [Allemagne] ; Marion [France]“Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients
000628 J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France]N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
000629 Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
000630 Roberto Marconi [France, Italie] ; Dominique Lefebvre-Caparros [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Bruno Dubois [France] ; Agid [France]Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
000638 Broussolle [France] ; L. Cinotti [France] ; Pierre Pollak [France] ; P. Landais [France] ; D. Le Bars [France] ; G. Galy [France] ; F. Lavenne [France] ; Y. Khalfallah [France] ; G. Chazot [France] ; F. Mauguière [France]Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease
000647 H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France]Symptomatic effect of selegiline in De Novo Parkinsonian patients
000654 Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse]Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
000670 Emmanuelle Pourcher [France] ; Anne-Marie Bonnet [France] ; John Kefalos [France] ; Bruno Dubois [France] ; Agid [France]Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease
000672 J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse]Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
000677 J. L. Montastruc [France] ; Celsis [France] ; A. Agniel [France] ; J. F. Demonet [France] ; B. Doyon [France] ; M. Puel [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France]Levodopa‐induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024